Analysts expect Novadaq Technologies Inc. (TSE:NDQ) to report $0.00 EPS on April, 26. About 2,500 shares traded. Novadaq Technologies Inc. (TSE:NDQ) has declined 34.87% since September 12, 2016 and is downtrending. It has underperformed by 43.35% the S&P500.
Ichor Holdings Ord (NASDAQ:ICHR) had a decrease of 30.79% in short interest. ICHR’s SI was 22,700 shares in April as released by FINRA. Its down 30.79% from 32,800 shares previously. With 172,600 avg volume, 0 days are for Ichor Holdings Ord (NASDAQ:ICHR)’s short sellers to cover ICHR’s short positions. The SI to Ichor Holdings Ord’s float is 0.31%. About 86,831 shares traded. Ichor Holdings Ltd (NASDAQ:ICHR) has risen 6.00% since March 20, 2017 and is uptrending. It has underperformed by 2.48% the S&P500.
Ichor Holdings, Ltd. is engaged in the design, engineering and manufacturing of critical fluid delivery subsystems for semiconductor capital equipment. The company has market cap of $457.66 million. The Company’s primary offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. It has a 20.93 P/E ratio. The Company’s gas delivery subsystems deliver, monitor and control precise quantities of the specialized gases used in semiconductor manufacturing processes, such as etch and deposition.
Among 3 analysts covering ICHOR Corporation (NASDAQ:ICHR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ICHOR Corporation had 4 analyst reports since January 11, 2017 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, January 11 report. The company was maintained on Friday, February 10 by Needham. Cowen & Co maintained the stock with “Buy” rating in Wednesday, February 8 report. Cowen & Co maintained the shares of ICHR in report on Wednesday, January 11 with “Outperform” rating.
NOVADAQ Technologies Inc. is a medical device company. The company has market cap of $588.79 million. The Firm primarily develops, makes and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. It currently has negative earnings. The Company’s SPY fluorescence imaging technology platform provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic.
